Preclinical studies indicate that, despite treatment with lapatinib, there is HER3 and residual HER2 activity in the GC cell lines, which allows NRG1 to counteract lapatinib-induced cell cycle arrest and apoptosis [129]. Here, NRG1 is linked to gastric cancer.